Table 4: Change from baseline to Week 24 in disease activity measures and subject reported outcomes.

FAS 
SC-TCZM 
SC-TCZC 

DAS28-ESR
471433
Mean change (SD)−4.4 (1.5)−4.3 (1.1)−4.4 (1.7)
,
ACR20 response at Week 24
(%)43 (91.5%)12 (85.7%)31 (93.9%)
95% CI79.6% to 97.6%57.2% to 98.2%79.8% to 99.2%
ACR50 response at Week 24
(%)36 (76.6%)11 (78.6%)25 (75.8%)
95% CI62.0% to 87.7%49.2% to 95.3%57.7% to 88.9%
()
ACR70 response at Week 24
(%)25 (53.2%)9 (64.3%)16 (48.5%)
95% CI38.1% to 67.9%35.1% to 87.2%30.8% to 66.5%
(
SDAI
451233
Mean change (SD)−31.6 (16.5)−34.1 (14.2)−30.7 (17.3)
CDAI
461333
Mean change (SD)−30.0 (15.1)−33.6 (13.1)−28.6 (15.8)
TJC28
471433
Mean change (SD)−11.1 (7.6)−11.4 (7.3)−10.9 (7.8)
SJC28
471433
Mean change (SD)−8.8 (6.0)−9.5 (6.3)−8.45 (5.9)
Physician’s global assessment of disease activity (VAS)
461333
Mean change (SD)−48.8 (21.3)−55.5 (24.4)−46.2 (19.8)
Patient’s global assessment of disease (VAS)
471433
Mean change (SD)−48.6 (25.9)−52.3 (26.7)−47.0 (25.8)
Patient’s global assessment of pain (VAS)
471433
Mean change (SD)−41.9 (27.0)−47.0 (31.0)−39.7 (25.3)
FACIT-F
471433
Mean change (SD)12.6 (10.5)15.6 (10.5)11.4 (10.5)
HAQ-DI
471433
Mean change (SD)−0.78 (0.59)−0.79 (0.70)−0.77 (0.54)

test used to test the hypothesis of no change from baseline to Week 24; Rank Sum test used to test the hypothesis of no change from baseline between the subgroups; ’s Exact test used to test the hypothesis of no difference between subgroups at Week 24; ACR20/50/70 20%/50%/70% improvement in the American College of Rheumatology response scores; CDAI, Clinical Disease Activity Index; DAS28-ESR, disease activity score (28 joints)-erythrocyte sedimentation rate; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; FAS, full analysis set; HAQ-DI, Health Assessment Questionnaire-Disability Index; SC-TCZC, subcutaneous tocilizumab combination therapy subgroup (including MTX); SC-TCZM, subcutaneous tocilizumab monotherapy subgroup (including DMARD(s) but excluding MTX); SDAI, Simplified Disease Activity Index; SJC28, swollen joint count (28 joints); TJC, tender joint count (28 joints); VAS, visual analogue scale; CI, confidence intervals.